ArticleOphthalmology2010
Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction.
Article in Ophthalmology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00709319 (Evaluation of Vitrectomy for Diabetic Macular Edema Study), which is not on this map. Cited by 114 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Vitrectomy for Diabetic Macular Edema Study
Who cites it
114 citing papers in PubMed, 2 syntheses or guidelines pooled it, 281 citations in OpenAlex.
- Aflibercept for long-term treatment of diabetic macular edema and proliferative diabetic retinopathy: a meta-analysis.Frontiers in endocrinology · 2023Pooled it
- ILM peeling in nontractional diabetic macular edema: review and metanalysis.International ophthalmology · 2018Pooled it
- Pars Plana Vitrectomy with Internal Limiting Membrane Peeling for Treatment-Naïve Diabetic Macular Edema: A Prospective, Uncontrolled Pilot Study.Clinical ophthalmology (Auckland, N.Z.) · 2021Trial
- Effects of kallidinogenase in patients undergoing vitrectomy for diabetic macular edema.International ophthalmology · 2019Trial
- Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.Ophthalmology · 2018Trial
- Concurrent vitrectomy with phacoemulsification for subclinical diabetic macular edema: a long-term comparative study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Beyond Anti-VEGF: Toward Integrated Precision Care in Diabetic Retinal Disease.Pharmaceutics · 2026Review
- Treatment-Emergent Epiretinal Membrane in Diabetic Macular Edema: A Real-World OCT-Based Comparative Pharmacotherapy Study Across Intravitreal Agents-The TRIDENT-DME Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Pharmacological Treatment for Diabetic Macular Edema: A 2025 Update on Durability and Multi-Target Therapies.Drug design, development and therapy · 2026Review
- Ten-Year Follow-Up of Visual Outcomes After Vitrectomy for Clinically Non-Tractional Diabetic Macular Edema.Cureus · 2025Article
- Efficacy of vitrectomy combined with and without cataract surgery for diabetic macular edema: one-year follow-up multi-center study in Japan.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Modulation of Oxidative Stress in Diabetic Retinopathy: Therapeutic Role of Natural Polyphenols.Antioxidants (Basel, Switzerland) · 2025Review
- Preventive and therapeutic strategies via health care delivery system to minimize sight-threatening diabetic retinopathy: a narrative review.Current diabetes reports · 2025Review
- Pars Plana Vitrectomy and ILM Peeling for Refractory Diabetic Macular Edema Without Vitreomacular Traction.Journal of clinical medicine · 2025Article
- Serum Apolipoprotein B and B/A1 Ratio as Early Negative Biomarkers for OCT- and OCTA-Detected Retinal Changes in Diabetic Macular Edema.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Real-World Outcomes of Different Types of Treatment for Diabetic Macular Edema Before and After Approval of Anti-Vascular Endothelium Growth Factor Agents.Journal of clinical medicine · 2024Article
- Intraoperative OCT-Guided Selective Epiretinal Membrane (ERM) Peeling Versus ERM and Internal Limiting Membrane Peeling for Tractional Macular Edema in Diabetic Eyes.Diagnostics (Basel, Switzerland) · 2024Article
- Fluocinolone Acetonide Implant for Uveitis: Dissecting Responder and Non-Responder Outcomes at a Tertiary Center.Biomedicines · 2024Article
- Article
- Pathological Neurovascular Unit Mapping onto Multimodal Imaging in Diabetic Macular Edema.Medicina (Kaunas, Lithuania) · 2023Review
54 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo evaluate vitrectomy for diabetic macular edema (DME) in eyes with at least moderate vision loss and vitreomacular traction.
designProspective cohort study.
participantsThe primary cohort included 87 eyes with DME and vitreomacular traction based on investigator's evaluation, visual acuity 20/63-20/400, optical coherence tomography (OCT) central subfield >300 microns and no concomitant cataract extraction at the time of vitrectomy.
methodsSurgery was performed according to the investigator's usual routine. Follow-up visits were performed after 3 months, 6 months (primary end point), and 1 year.
main outcome measuresVisual acuity, OCT retinal thickening, and operative complications.
resultsAt baseline, median visual acuity in the 87 eyes was 20/100 and median OCT thickness was 491 microns. During vitrectomy, additional procedures included epiretinal membrane peeling in 61%, internal limiting membrane peeling in 54%, panretinal photocoagulation in 40%, and injection of corticosteroids at the close of the procedure in 64%. At 6 months, median OCT central subfield thickness decreased by 160 microns, with 43% having central subfield thickness <250 microns and 68% having at least a 50% reduction in thickening. Visual acuity improved by > or =10 letters in 38% (95% confidence interval, 28%-49%) and deteriorated by > or =10 letters in 22% (95% confidence interval, 13%-31%). Postoperative complications through 6 months included vitreous hemorrhage (5 eyes), elevated intraocular pressure requiring treatment (7 eyes), retinal detachment (3 eyes), and endophthalmitis (1 eye). Few changes in results were noted between 6 months and 1 year.
conclusionsAfter vitrectomy performed for DME and vitreomacular traction, retinal thickening was reduced in most eyes. Between 28% and 49% of eyes with characteristics similar to those included in this study are likely to have improvement of visual acuity, whereas between 13% and 31% are likely to have worsening. The operative complication rate is low and similar to what has been reported for this procedure. These data provide estimates of surgical outcomes and serve as a reference for future studies that might consider vitrectomy for DME in eyes with at least moderate vision loss and vitreomacular traction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.